K

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Director – Analytical Development and Quality Control

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • At least 10 years of experience in the pharmaceutical or biotechnology industry, or at least 8 years with an advanced degree, including experience in all phases of innovative drug development and commercial launch in accordance with global CMC regulatory filings (IND/NDA/MAA, etc.).
  • Strong expertise in analytical techniques including HPLC/UPLC, LC–MS, SE-HPLC, CCIT, and device testing.
  • Knowledge of drug development activities related to cGMP, quality systems, ICH guidelines, global regulatory requirements, and USP, EP, JP, and CHP requirements.
  • A strong track record of working with CROs/CMOs and managing external analytical development and QC activities.
  • Demonstrated leadership ability with experience mentoring and developing staff.
  • Strong communication, cross-functional collaboration, and project-management skills.
  • A bachelor's degree with 10+ years or an advanced degree with 8+ years of relevant experience.
  • A degree in Analytical Chemistry, Organic Chemistry, Physical Chemistry, Pharmaceutical Sciences, or a closely related field.

Responsibilities

  • Lead analytical development, control strategy, and lifecycle management for sterile injectable/parenteral products from development through commercialization, including method development, validation, transfer, QC implementation, and commercial support.
  • Define and execute analytical CMC strategies, regulatory submissions, and control frameworks, including NDA Module 3 content, analytical data packages, specifications, characterization, validation, stability, and commercial release requirements.
  • Ensure scientifically sound, regulatory-compliant analytical programs by leading technical issue resolution, risk management, resource planning, agency interactions, and compliance with FDA, ICH, and pharmacopeial expectations.
  • Provide analytical leadership for product characterization, stability, microbiological strategies, quality attributes, commercial manufacturing support, and investigations related to analytical trends, deviations, and product quality issues.
  • Establish and maintain robust analytical methods through risk-based qualification, validation, lifecycle management, continuous improvement, troubleshooting, performance monitoring, revalidation, and enhancement of method robustness and efficiency.
  • Lead stability and specification strategies across the product lifecycle, ensuring analytical data support shelf life, storage conditions, regulatory commitments, product release, and commercialization objectives.
  • Integrate analytical, formulation, process, and manufacturing knowledge to support technology transfer, comparability assessments, change management, and oversight of external analytical laboratories and partners.

Desired Qualifications

  • Prior experience supporting development of peptide sterile injectable/combination drug products.
  • Experience supporting commercial products.
  • Knowledge of combination product testing and control strategy.

About the Company

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Kailera Therapeutics focuses on obesity and related metabolic conditions by acquiring and developing clinical-stage drug candidates and moving them toward commercialization. Its lead asset, KAI-9531, is an injectable dual agonist of GLP-1 and GIP receptors for obesity and type 2 diabetes, and the pipeline includes an oral GLP-1 agonist (KAI-7535), an oral tablet form of KAI-9531, and an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors (KAI-4729). The company differentiates itself by sourcing assets outside of early research, pursuing a mix of injectable and oral therapies, and leveraging a high-profile leadership team and substantial funding to progress a broad portfolio under external licenses. Kailera’s goal is to advance multiple metabolic disease therapies from clinical development toward commercialization to improve outcomes for patients with obesity and related conditions.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Kailera Therapeutics

See more jobs